
As NLRP3 players head for first clinical face-off, Novo, Sanofi fuel trans-Atlantic contender with $55M
In the relative short history of inflammasome research, Adam Keeney sees two time points marking major breakthroughs: the early 2000s, when the role of inflammasomes as a major innate immunity node was elucidated; and 2015, when scientists observed that an old Pfizer compound they thought were blocking IL-1 actually targeted NLRP3. Keeney’s biotech, NodThera, was founded the year after alongside several others to create its own superior small molecule drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.